HIMS — All updates

20 entries loaded; 0 direction changes

Filter loaded records
Schwab NetworkPublished 2026-11-18
“Wednesday's Final Takeaways: Gold at 52-Week Lows, Housing Market Mixed”
$HIMSNo side taken
AI summary · HIMS launched Peptides Plus with five combination therapies, which could draw new customers beyond traditional telehealth and add recurring revenue amid rising peptide demand, but none of the initial treatments is FDA-approved and HIMS says safety, effectiveness and dosing are still uncertain; regulatory and scientific risk could materially threaten its growth plans.

Hims&Hers may have missed out on the " hot peptide summer," but there may be a " hot peptide winter" coming, as it launches its new "Peptides Plus" platform offering five combination therapies targeting everything from energy and recovery to cellular health.

This move comes at a time when demand for peptides is increasing, but there is a major obstacle here . None of the initial treatments are approved by the Food and Drug Administration (FDA), and the company itself acknowledges that there is still much to learn about their safety, effectiveness, and appropriate dosages .

Verified InvestingPublished 2026-11-17
“MAJOR EARNINGS FOR NVIDIA (Silver Bottom?)”
$HIMSBullish
AI summary · HIMS is in a downtrend dating from just before May and, despite decent earnings, it fell and is still falling; the speaker will buy only if it drops to around 18 bucks, seen as a potential support area.

So with the markets generally kind of bouncing a little bit, I'm looking at something that might fall and is a little lower and that's HIMS HIMS. You have a nice downs sloping trend line from all the way back here just before May of this year coming through here coming through here and then finally looking for an area for potential support down here.

“NVDA Fallout: Where Is the Smart Money Going? | Market Pulse Nov. 13, 2026”
$HIMSBearish
AI summary · HIMS trended up for a long time, but after vaguely recalled account-related problems, it fell for consecutive weeks and gapped down in an exhaustion gap; the speaker concludes it has not recovered.

Let's take a look at the "Hems" company. It's called " [17:18] Hems & Hers Health". Now look at this [17:21] graph, don't you? It is clear that [17:24] this chart has been trending upwards for a long time [17:27] .

They encountered some problems with the accounts or something like that [17:29] . I can't remember. But [17:32] look at all those consecutive weeks of [17:35] decline, until the stock eventually gapped down [17:37] , and that was an exhaustion gap. He [17:39] really couldn't recover, did he?

Parkev Tatevosian, CFAPublished 2026-11-13
“Why Is Hims Stock Crashing, and is it a Buying Opportunity?”
$HIMSBullish
AI summary · HIMS remains a buying opportunity, but his conviction has dropped from moderate to low because expenses grew faster than revenue: G&A nearly doubled to $151.5M, operating income fell to -$66M from $11.8M and operating cash flow dropped to $119M from $239M, making the ~18% drop logical. Despite 49% revenue growth, 13% subscriber growth and 30% higher revenue per subscriber, at $19 the stock is undervalued versus his slightly above $22 fair value and a 25.4 forward P/E.

Hems & Hers announced quarterly financial results that disappointed investors in the stock market. Revenues increased by 49% and subscribers by 13%, but expenses also increased and cash flow decreased significantly.

Investors punished the stock, which fell by about 19 % the day after the company announced these figures. So I wanted to share my rating of Heams & Hers stock, whether I think this represents a buying opportunity after the price drop , and what my estimate of the company's fair value is.

“Hims & Hers Collapses 30% In a Week”
$HIMSBullish
AI summary · HIMS fell 18% after a disappointing quarter: subscribers fell about 100,000 QoQ, gross margin dropped from 83% to 57% on branded GLP-1 mix, Q4 revenue is guided slightly down and full-year adjusted EBIT guidance was cut. The speaker is not selling and still calls HIMS a great company to own over 5-10 years, based on its higher-priced subscription, TRT and peptide strategy and Costco-like health-subscription model, with management betting on Q1 2027; short-term subscriber growth and competition leave questions, and next quarter's guidance is important.

Shares of his and hers are down 18% in late trading on Tuesday after their company reported earnings on Monday. The investors did not like what they heard from the earnings report.

In a lot of ways, the report was really disappointing. The number of subscribers was down quarter over quarter. Gross margins continued to be under pressure. And management said that they were actually not spending as much to bring in those new customers. That's why growth really slowed.

The Motley FoolPublished 2026-11-10
“Stock Market Update: Rising Rates & Falling Stocks”
$HIMSNo side taken
Schwab NetworkPublished 2026-11-10
“HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus”
$HIMSNo side taken
The Motley FoolPublished 2026-11-05
“Market Crash Live: Why AI Stocks Are Plunging & What We're Doing Now”
$HIMSBullish
“Hims & Hers: The 10x Stock You Can't Ignore”
$HIMSBullish
AI summary · HIMS is highly undervalued: it leads a huge US pharma market with 51% observed sales share, is expanding products and internationally, and its peptides could become over a billion dollars by end-2027. Revenue is about $2.6 billion, management guides 50% annual growth in 2H 2026, and peptides could lift revenue to $5-6 billion in a few years; near 1x price-to-sales, that growth deserves a higher multiple. Risks include management stretching across markets, though he backs the team.

In my opinion, one of the companies that has huge opportunities for investors is Hims& Hers. This company is trying to radically change one of the largest industries in the world, namely the medical industry and the pharmaceutical industry.

The pharmaceutical industry is worth about $400 billion in the United States alone. From what I see now, HimsandHers has a market capitalization of only about $6.4 billion. This is a company whose value could increase not just 10 times, but potentially 100 times in the next 10 or 20 years.

Parkev Tatevosian, CFAPublished 2026-10-18
“Hims Is Reaching 3 Million Member Milestone”
$HIMSBullish
The Motley FoolPublished 2026-10-14
“4 Stocks to Buy Now and Hold for the Next Decade”
$HIMSBullish
AI summary · HIMS is a bullish, riskier long-term holding: it is disrupting healthcare, grew 60% CAGR since 2020 and forecasts 50% Y/Y revenue growth in H2 2026, usually beats; Lilly/Novo deals stabilize it. Its AI/data platform could become a central healthcare repository. At 3x sales, ignores profitability, plans hold to 2030.

Okay, let's move on to talking about slightly more risky companies. We may have put Mercado Libre on the riskier side, but it 's probably on par with Hems & Hers, which is the third stock I wanted to talk about.

Hems & Hers is one of the companies that is revolutionizing healthcare in many different ways. It makes accessing services really easier because you access them via the internet or an app, and you communicate with the doctor instead of actually going to his clinic, providing your insurance, and then going to the pharmacy.

If you have children like us, it's extremely annoying, isn't it? Especially for ordinary things. So, they don't cover all disciplines right now, but think about their position 10 years from now, when they will move from five or six disciplines today to perhaps most of the needs that are constantly required.

“Why I'm Betting Big on These 5 Growth Stocks”
$HIMSBullish
AI summary · Hims and Hers has strong long-term growth potential; guided to 50% revenue growth in H2 2026 following regulatory settlements and portfolio expansion.

Speaking of companies that have a lot of growth runway ahead, Himson and Hers had a tough start to 2026, but the second half of 2026, their guidance is that they're going to grow revenue at 50%.

So, if we look at their component annual growth rate over the past 3 years, 54%, stocks pretty cheap. Enterprise value to sales about 2.8. That could significantly increase forward price earnings multiple 81.

We're not focused on profitability yet for his and hers, but let's look at what's happened over the past year or so.

The Motley FoolPublished 2026-10-01
“The Truth About Hims & Hers Stock: A Deep Dive”
$HIMSNo side taken
AI summary · HIMS is a high-risk speculative buy; huge TAM and >50% growth potential are balanced against strong competition, regulatory ambiguity, and margin compression risks.

Hims & Hers is one of the most talked-about stocks in the market. It is also one of the most volatile stocks . The stock has risen by 250% over the past five years , but if you look at it over the past year, the stock has fallen by about 50%. There's a lot going on inside the company.

Schwab NetworkPublished 2026-09-18
“40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"”
$HIMSBullish
AI summary · HIMS is undervalued and poised for upside; its platform model captures value from any winning GLP-1 drug, and short-selling pressure will diminish as market cap grows.

I want to talk about the company "Hems & Hers Health". This is another name that is attracting a lot of attention, especially on social media. It's a volatile stock, but it seems to be in a transitional phase, and I'm interested to know your opinion on its role in this area, and your general opinion of the company .

Parkev Tatevosian, CFAPublished 2026-09-16
“Is Hims & Hers Stock a Buy Right Now in September? | HIMS Stock Analysis”
$HIMSBullish
AI summary · HIMS is a buy for high-risk-tolerance long-term investors due to strong growth prospects and fair valuation.

Hims & Hers management team reiterated its longer-term guidance to investors. The management team is forecasting at least $6.5 billion in revenue by 2030 and $1.3 billion in adjusted earnings before interest, taxes, depreciation, and amortization.

But does this make Hims & Hers stock a buying opportunity for long-term investors? So, revenue of at least $6 billion by 2030 would be more than double their most recent trailing 12-month total.

In that period, Hims & Hers reported $2.6 billion in revenue. That's up from around $250 million in 2020. This has been one of the fastest-growing companies in the world.

“The Hims & Hers Australia Strategy: Why It Matters for Investors”
$HIMSBullish
AI summary · HIMS is a high-growth asymmetric investment case; becoming the global healthcare demand aggregator could increase value 10-100x.

Being a leading telehealth company in the US could be a 10x, maybe even a bigger opportunity for Hims & Hers, but beating being the global telehealth company where you go to answer all your questions no matter where you are in the world is really where the massive opportunity is for healthcare and for Hims & Hers.

Financial EducationPublished 2026-08-24
“This Stock will make us RICH🤑AF”
$HIMSNo side taken
AI summary · HIMS faces frequent negative news; holding requires strong conviction to avoid being shaken out.

Number one, we're going to discuss Hims stock in this video, okay? There was some news that came out in regards to Hims. Stock went down heavy. I want to talk about that.

Hims stock got hammered here today, down 8% roughly, right? Tough day for Hims stock. Of the stocks on my watchlist, you know, 4000xstocks.com, that was the worst performer here today.

“4 Incredible Stocks I Love Today”
$HIMSBullish
AI summary · Hims & Hers is a long-term growth stock with strong potential, supported by reaccelerating revenue growth, subscriber growth, and margin expansion opportunities.

Hims & Hers, as for everything that it has gone through this year, is actually still down almost 20% for the year, but you can see shares bottomed in late February. Since then, up nearly 100% pulled back just a little bit.

They were trading at nearly $40 per share in early July. So, since then, down about 25%. Very volatile stock. So, something to keep in mind for investors.

What they said to watch for
See older →
All updates for other tickers
Follow $HIMS30-day free trial
Start trial